Positive Test Results Propel CRNX Stock to New Heights
Crinetics Pharmaceuticals, Inc. (CRNX) witnessed a remarkable 19.1% surge in its stock price, closing at $45.18 in the most recent trading session. This jump was accompanied by robust trading volume, signifying heightened investor interest. The stock’s current ascent starkly contrasts with its modest 0.3% gain over the past four weeks.
Breakthroughs in Medical Studies Drive Investor Enthusiasm
The unprecedented spike in CRNX was ignited by the revelation that the company had achieved primary and secondary endpoints of its second late-stage study, PATHFNDR-2. This study focused on evaluating paltusotine, the lead candidate for acromegaly treatment. Prior to this, Crinetics had already reported successful outcomes in the phase III PATHFNDR-1 trial. Bolstered by the promising results from both late-stage studies, the company now gears up to seek FDA approval for paltusotine in acromegaly treatment, with plans to submit the regulatory application in the latter half of 2024.
The Quandary of Future Earnings and Revenue Projections
In anticipation of the upcoming quarterly report, Crinetics Pharmaceuticals is expected to incur a loss of $0.84 per share, marking a slight year-over-year increase of 1.2%. Although revenues are projected to dip by 69.6% to $0.82 million compared to the same quarter last year, investors are closely monitoring the trajectory of earnings estimate revisions. Research indicates a strong correlation between these revisions and short-term stock price movements, highlighting the significance of upcoming financial disclosures.
Implications from Zacks Rankings and Industry Comparisons
Currently holding a Zacks Rank #3 (Hold), Crinetics Pharmaceuticals is positioned within the Zacks Medical – Drugs industry. Contrastingly, Catalyst Pharmaceutical (CPRX), another player in the same sector, observed a 1.9% increase in its stock price, closing at $16.39 in the latest trading session. Comparing the two, CPRX has demonstrated a 14.9% return in the past month. However, with a consensus EPS estimate revision of -28.4% for the upcoming report, Catalyst currently carries a Zacks Rank of #4 (Sell), highlighting diverging market perspectives between the two pharmaceutical entities.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report.
Crinetics Pharmaceuticals, Inc. (CRNX) : Free Stock Analysis Report
Catalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
